News Releases

News and information from The Leukemia & Lymphoma Society

FDA Approves New Targeted Therapy for AML

Rye Brook, N.Y. (August 1, 2017) – Today marks another significant advance in the offensive against acute myeloid leukemia (AML), one of the most deadly blood cancers that takes more than 10,000 lives in the U.S. each year. The Leukemia & Lymphoma Society (LLS) applauds The U.S. Food & Drug Administration’s approval today of a new targeted therapy, enasidenib (IDHIFA®), for patients with AML, who ha...

‘SKINNY’ SENATE HEALTHCARE BILL WOULD THREATEN ACCESS TO CANCER TREATMENT

Rye Brook, N.Y. (July 26, 2017) – The U.S. Senate has initiated debate on the House-passed healthcare bill, and Senate leaders are indicating they intend to advance legislation they have termed ‘skinny repeal.’ This Senate proposal would increase premiums and cost-sharing for patients who purchase their own insurance plans, while leading some insurers to stop selling non-group coverage altogether, according to ...

LLS Announces Expansion of Precision Medicine Approach to Fight Blood Cancer

Rye Brook, NY (July 19, 2017) – The Leukemia & Lymphoma Society (LLS) today announced the expansion of its groundbreaking precision medicine Beat AML® Master Trial, to test new, investigational treatments for acute myeloid leukemia (AML), the central initiative of LLS’s comprehensive assault on this deadly blood cancer affecting 20,000 Americans annually. Launched in October 2016, the master trial has exc...

Man & Woman of the Year is Proof Individuals can Impact Cancer Cures

View multimedia release here.  Rye Brook, NY (July 13, 2017) – As the leader in peer-to-peer fundraising for almost 70 years, The Leukemia & Lymphoma Society (LLS) continues to find ways to reinvent the way health charities raise vital funds for research and patient support. After pioneering non-profit sports training with Team In Training, LLS turned the traditional walk into a community experienc...

Pages

Media Contact

Have media inquiries? Contact us between 9 a.m. and 5 p.m. ET, Monday through Friday: